Posts Tagged: "Ranbaxy"

Mark Lemley’s Firm Files DJ Against Myriad in Northern California —– Promise Not to Infringe Insufficient in ANDA Litigation —– Licensing Deals Stall in Pharmaceutical Sector in First Half of 2013 —– Mylan Settles with FTC over Agila Acquisition from Strides —– Amgen and ShanghaiTech University Announce China R&D Center —– Forest Laboratories sues over SAVELLA® generics —– Teva Pharmaceutical scores patent cictory over Mylan on AZILECT® —– Patent Awarded to New Hepatitis C Treatment —– Orphan drug designation for treatment of Acute Radiation Syndrome —– Avanir settles ANDA litigation with Actavis over NUEDEXTA

Once again, a plethora of interesting events has occurred since the last time we stopped by. What was the biggest headline? That decision may be up for grabs, but certainly, the $500 million penalty paid by Ranbaxy Laboratories is high on the list. In other news, yet another Johnson & Johnson manufacturing scandal has erupted, this time in South Korea, where the authorities plan to bring criminal charges against its Janssen unit and ban production of five products – notably, a type of Children’s Tylenol. A non-profit group put Bayer on notice that a lawsuit will be filed charging the drugmaker with making “unsubstantiated and illegal claims” about the ability of its One-A-Day vitamin to prevent various disease, such as breast cancer, bolster physical energy and improve immunity, among other things.

Litigation always factors into the pharmaceutical world, but the US Supreme Court commanded a special place in recent days. The high court figured in no fewer than four contentious issues that, not surprisingly, play a vital role in how drug makers can and will operate. Let’s start with a case that is not yet before the court, but many predict will be headed there thanks to one of its earlier rulings. Earlier this month, a three-judge panel of the US Court of Appeals for the Second Circuit overturned the conviction of a former sales representative, who argued that prosecuting him for remarks made about off-label use violated his free speech rights.